Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium Thiosulfate for Critically Ill COVID-19 Patients
NCT05277285Phase 2Unknown
- Sponsor
- Hellenic Institute for the Study of Sepsis
- Start
- Apr 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sodium thiosulfate in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Hellenic Institute for the Study of Sepsis. Primary endpoint: Adverse Events at 28 days. Status: unknown.
02
Drugs
sodium thiosulfate
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05277285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05277285.